Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation

Addiction

Volumn 107, Issue 1, 2012, Pages 178-187

  Quaak, Marieke ^a,b   van Schayck, Constant P ^b   Postma, Dirkje S ^c   Wagena, Edwin J ^b,d   van Schooten, Frederik J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Kiadis Pharma   (Netherlands)

Author keywords

5 HTTLPR; Bupropion; Nortriptyline; Pharmacogenetics; Rs25331; Serotonin plasma membrane transport protein (5 HTT) gene (SLC6A4); Smoking cessation; STin2 VNTR

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NORTRIPTYLINE; PLACEBO; SEROTONIN TRANSPORTER;

ALLELE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

ALLELES; ANTIDEPRESSIVE AGENTS; BUPROPION; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; NORTRIPTYLINE; PLACEBOS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 83355163268     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03534.x     Document Type: Article

References (29)

1. Quaak M., van Schayck C. P., Knaapen A. M., van Schooten F. J. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J 2009; 33: 468-80.
2. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984; 104: 277-86.
3. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999; 19: 467-89.
4. Dwoskin L. P., Rauhut A. S., King-Pospisil K. A., Bardo M. T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006; 12: 178-207.
5. Paterson N. E. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol 2009; 603: 1-11.
6. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D. etal. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-4.
7. Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S. etal. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
8. Fiskerstrand C. E., Lovejoy E. A., Quinn J. P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 1999; 458: 171-4.
9. MacKenzie A., Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 1999; 96: 15251-5.
10. Kraft J. B., Slager S. L., McGrath P. J., Hamilton S. P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374-81.
11. Hu X., Oroszi G., Chun J., Smith T. L., Goldman D., Schuckit M. A. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 2005; 29: 8-16.
12. Wagena E. J., Knipschild P. G., Huibers M. J., Wouters E. F., van Schayck C. P. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 2286-92.
13. Van Schayck C. P., Kaper J., Wagena E. J., Wouters E. F., Severens J. L. The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction 2009; 104: 2110-7.
14. Hughes J. R., Keely J., Niaura R. S., Ossip-Klein D. J., Richmond R. L., Swan G. E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003; 5: 13-26 [published correction in Nicotine Tob Res. 2003; 5: 603].
15. Jarvis M. J., Tunstall-Pedoe H., Feyerabend C., Vesey C., Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 1987; 77: 1435-8.
16. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerström K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-27.
17. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD Report. Update 2010. Available at: (accessed 11 July 2011; archived by Webcite at).
18. Wendland J. R., Martin B. J., Kruse M. R., Lesch K. P., Murphy D. L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006; 11: 224-6.
19. Seth P., Cheeta S., Tucci S., File S. E. Nicotinic-serotonergic interactions in brain and behaviour. Pharmacol Biochem Behav 2002; 71: 795-805.
20. Dong J., Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155: 52-7.
21. El Mansari M., Ghanbari R., Janssen S., Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008; 55: 1191-8.
22. Han D. H., Joe K. H., Na C., Lee Y. S. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet 2008; 18: 11-6.
23. Lerman C., Audrain J., Orleans C. T., Boyd R., Gold K., Main D. etal. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 1996; 21: 9-19.
24. David S. P., Munafo M. R., Murphy M. F., Walton R. T., Johnstone E. C. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 2007; 9: 225-31.
25. Munafo M. R., Johnstone E. C., Wileyto E. P., Shields P. G., Elliot K. M., Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 398-400.
26. David S. P., Johnstone E. C., Murphy M. F., Eveyard P., Guo B., Lerman C. etal. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend 2008; 98: 77-85.
27. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1 CD000031. DOI: 10.1002/14651858.CD000031.pub3.
28. Smits K. M., Smits L. J., Schouten J. S., Stelma F. F., Nelemans P., Prins M. H. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9: 433-41.
29. Lundback B., Gulsvik A., Albers M., Bakke P., Ronmark E., van den Boom G. etal. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl 2003; 40: 3s-9s.